BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Liao L, Li Y, Huang H, Huang Q, Deng S. Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Biomed Res Int 2020;2020:7653506. [PMID: 33102593 DOI: 10.1155/2020/7653506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Zhang X, Chen Y, Cai G, Li X, Wang D. Carnosic acid induces apoptosis of hepatocellular carcinoma cells via ROS-mediated mitochondrial pathway. Chem Biol Interact 2017;277:91-100. [PMID: 28918123 DOI: 10.1016/j.cbi.2017.09.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
3 Xu S, Shu P, Zou S, Shen X, Qu Y, Zhang Y, Sun K, Zhang J. NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway. Cancer Med 2018;7:4701-17. [PMID: 30085405 DOI: 10.1002/cam4.1716] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis 2019;6:419-30. [PMID: 31832522 DOI: 10.1016/j.gendis.2019.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
5 Takahashi K, Putchakayala KG, Safwan M, Kim DY. Extrahepatic metastasis of hepatocellular carcinoma to the paravertebral muscle: A case report. World J Hepatol 2017; 9(22): 973-978 [PMID: 28839518 DOI: 10.4254/wjh.v9.i22.973] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
6 Su WH, Jou YS, Zhang JH, Ho CM, Tai DI. Mutations in NOTCH1 and nucleotide excision repair genes are correlated with prognosis of hepatitis B virus-associated hepatocellular carcinoma. J Cancer 2018;9:2678-86. [PMID: 30087708 DOI: 10.7150/jca.25438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Gui L, Zhu YW, Xu Q, Huang JJ, Hua P, Wu GJ, Lu J, Ni JB, Tang H, Zhang LL. RNA interference-mediated downregulation of phospholipid scramblase 1 expression in primary liver cancer in vitro. Oncol Lett 2020;20:361. [PMID: 33133261 DOI: 10.3892/ol.2020.12225] [Reference Citation Analysis]
8 Li R, Zhou S, Gan Z, Wang L, Yu Y. The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats. Molecules 2022;27:2594. [PMID: 35458793 DOI: 10.3390/molecules27082594] [Reference Citation Analysis]
9 Taskaeva YS, Bgatova NP. Ultrastructural Changes in Hepatocellular Carcinoma-29 Cells after Treatment with Lithium Carbonate. Bull Exp Biol Med 2019;167:87-90. [PMID: 31177458 DOI: 10.1007/s10517-019-04467-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Yang X, Xia W, Chen L, Wu CX, Zhang CC, Olson P, Wang XQ. Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma. Oncotarget 2018;9:34996-5007. [PMID: 30405889 DOI: 10.18632/oncotarget.26209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
11 Takahashi T, Deuschle U, Taira S, Nishida T, Fujimoto M, Hijikata T, Tsuneyama K. Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation. Hepatol Int 2018;12:254-61. [PMID: 29651702 DOI: 10.1007/s12072-018-9860-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Wen L, Hu Y, Meng T, Tan Y, Zhao M, Dai S, Yuan H, Hu F. Redox-responsive polymer inhibits macrophages uptake for effective intracellular gene delivery and enhanced cancer therapy. Colloids Surf B Biointerfaces 2019;175:392-402. [PMID: 30554018 DOI: 10.1016/j.colsurfb.2018.12.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
13 Li Y, McGrail DJ, Xu J, Li J, Liu NN, Sun M, Lin R, Pancsa R, Zhang J, Lee JS, Wang H, Mills GB, Li X, Yi S, Sahni N. MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology. Hepatology 2019;70:532-46. [PMID: 30153342 DOI: 10.1002/hep.30242] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
14 Hasan MN, Choudhry H, Razvi SS, Moselhy SS, Kumosani TA, Zamzami MA, Omran Z, Halwani MA, Al-Babili S, Abualnaja KO, Al-Malki AL, Alhosin M, Asami T. Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells. Bioorg Med Chem Lett 2018;28:1077-83. [PMID: 29456109 DOI: 10.1016/j.bmcl.2018.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Galal El-Shemi A, Mohammed Ashshi A, Oh E, Jung BK, Basalamah M, Alsaegh A, Yun CO. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma. Gene Ther 2018;25:54-65. [PMID: 28925992 DOI: 10.1038/gt.2017.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
16 Kim SH, Wang WH, Wang JP, Hsieh CH, Fang K. Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells. Biomed Pharmacother 2018;99:997-1008. [PMID: 29653488 DOI: 10.1016/j.biopha.2018.01.157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Liu X, Qin S. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist 2019;24:S3-S10. [PMID: 30819826 DOI: 10.1634/theoncologist.2019-IO-S1-s01] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
18 Saber S, Khodir AE, Soliman WE, Salama MM, Abdo WS, Elsaeed B, Nader K, Abdelnasser A, Megahed N, Basuony M, Shawky A, Mahmoud M, Medhat R, Eldin AS. Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity. Naunyn Schmiedebergs Arch Pharmacol 2019;392:1591-604. [PMID: 31367864 DOI: 10.1007/s00210-019-01706-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
19 Pu M, Wang J, Huang Q, Zhao G, Xia C, Shang R, Zhang Z, Bian Z, Yang X, Tao K. High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes. Tumour Biol 2017;39:101042831770912. [DOI: 10.1177/1010428317709127] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
20 Yu Q, Yang X, Duan W, Li C, Luo Y, Lu S. miRNA-346 promotes proliferation, migration and invasion in liver cancer. Oncol Lett 2017;14:3255-60. [PMID: 28927074 DOI: 10.3892/ol.2017.6561] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
21 Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma. Curr Med Chem 2019;26:1224-50. [PMID: 29303075 DOI: 10.2174/0929867325666180105103637] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
22 Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett 2019;459:156-67. [PMID: 31181320 DOI: 10.1016/j.canlet.2019.114429] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]